INmune Bio Reports Statistically Significant Treatment Effect on Advanced White Matter MRI Biomarker in Phase 2 MINDFuL Alzheimer's Trial

Stock Information for INmune Bio Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About INmune Bio Inc.

INmune Bio Inc. Achieves MHRA Approval of PIP for CORDStrom(TM)
INmune Bio Receives MHRA Written Alignment Supporting Planned 2026 UK Conditional Marketing Authorization Application for CORDStrom(TM) in RDEB
Three TriKE Candidates In Clinic As NK Cell Engager Field Reorganizes
INmune Bio Publishes Phase 2 MINDFuL Trial Results in NPJ Dementia, Advancing the XPro(TM) Platform
INmune Bio Receives FDA Fast Track Designation for XPro1595 in Early Alzheimer's Disease
INmune Bio Named Founding Member of the American Biotech Innovation Alliance (ABIA) as U.S. Biotech Sector Navigates Strategic Inflection Point
INmune Bio Inc. Announces First Quarter 2026 Results and Provides Business Update
INmune Bio and Anthony Nolan Announce Strategic Expansion of CORDStrom(TM) MSC Platform Collaboration to Target RDEB, Oncology, and Inflammatory Diseases

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.